46.19
前日終値:
$45.64
開ける:
$45.98
24時間の取引高:
791.01K
Relative Volume:
0.36
時価総額:
$113.58B
収益:
$48.62B
当期純損益:
$6.80B
株価収益率:
16.47
EPS:
2.8038
ネットキャッシュフロー:
$7.62B
1週間 パフォーマンス:
-8.29%
1か月 パフォーマンス:
-5.82%
6か月 パフォーマンス:
-14.99%
1年 パフォーマンス:
-10.58%
Sanofi Adr Stock (SNY) Company Profile
SNY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
46.26 | 120.12B | 48.62B | 6.80B | 7.62B | 2.8038 |
![]()
LLY
Lilly Eli Co
|
755.46 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
165.71 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
193.72 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
114.14 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
MRK
Merck Co Inc
|
78.42 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
2025-03-21 | 開始されました | Goldman | Neutral |
2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
2024-07-26 | 繰り返されました | Argus | Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-10-30 | ダウングレード | Stifel | Buy → Hold |
2023-09-06 | アップグレード | Berenberg | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
2022-12-13 | 再開されました | Morgan Stanley | Overweight |
2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
2022-08-09 | ダウングレード | UBS | Buy → Neutral |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 開始されました | Deutsche Bank | Sell |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
2020-03-11 | アップグレード | Goldman | Neutral → Buy |
2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 開始されました | Bernstein | Outperform |
2019-08-14 | アップグレード | UBS | Neutral → Buy |
2018-12-11 | アップグレード | Jefferies | Hold → Buy |
2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
2018-03-23 | アップグレード | Liberum | Hold → Buy |
2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):